Pasithea Therapeutics (KTTA) Operating Expenses (2021 - 2026)

Pasithea Therapeutics' Operating Expenses history runs 6 years deep, the most recent figure standing at $4.9 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 32.49% year-over-year to $4.9 million; the TTM figure through Mar 2026 stood at $22.1 million (up 58.77% YoY), while the FY2025 annual figure was $20.9 million, up 46.37% from the prior year.
• Operating Expenses came in at $4.9 million for Q1 2026 at Pasithea Therapeutics, down from $10.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $10.3 million in Q4 2025 to a low of $2.6 million in Q3 2022.
• A 5-year average of $4.0 million and a median of $3.8 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses jumped 397.01% in 2022 and slumped 36.69% in 2024, its largest moves.
• Pasithea Therapeutics' Operating Expenses stood at $4.0 million in 2022, then climbed by 27.36% to $5.1 million in 2023, then plunged by 36.69% to $3.3 million in 2024, then soared by 214.65% to $10.3 million in 2025, then slumped by 52.45% to $4.9 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $4.9 million, $10.3 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison